Next, to investigate whether SY-1530 blocked the BCR signaling pathway similarly to ibrutinib, we treated several B-cell lymphoma cell lines with a series of concentrations of inhibitors, washed them with PBS, and stimulated them with anti-IgM/anti-IgG. Here, BCR is linked to B-cell non-Hodgkin lymphoma.